DDXSQ

 
Common Stock SEC Reporting - Delinquent
OTC Pink No Information
Contact Info
  • 349 Oyster Point Boulevard
  • South San Francisco, CA 94080

Business Description


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Mar 31, 2016 10-Q
CIK 0001036968
Fiscal Year End 12/31
OTC Marketplace OTC Pink No Information
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 1995
Employees 41 a/o Oct 01, 2015
Company Officers/Contacts
Lori F. Rafield CEO
Kenneth C Fang, M.D. Chief Med. Officer
Xiaoyan Yan Zhao Corporate Controller
Company Directors
Lori F. Rafield Chairman
Karen Drexler
John Curnutte, M.D., Ph.D
Elizabeth Hutt Pollard
James Sulat
Company Notes
  • Note = Core Resource Management filed for Chapter 11 protection with the U.S. Bankruptcy Court in the District of Arizona, case number 16- 06712 on 6-15-2016
  • Formerly=diaDexus, Inc. until 7-2015
  • Formerly=VaxGen, Inc. until 11-2010
Service Providers
Accounting/Auditing Firm
PricewaterhouseCoopers LLC
488 Almaden Boulevard
Suite 1800
San Jose, CA, 95110
United States

Legal Counsel
Cooley LLP
101 California Street
5th Floor
San Francisco, CA, 94111-5800
United States

Investor Relations Firm
Argot Partners
200 Park Avenue South
Suite 1515
New York, NY, 10003
United States

DDXSQ Security Details
Share Structure
Market Value1 $94,301 a/o Dec 07, 2016
Authorized Shares 50,000,000 a/o Jul 01, 2015
Outstanding Shares 4,100,060 a/o Oct 29, 2015
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Shareholders
Shareholders of Record 72 a/o Mar 29, 2016
Short Selling Data
Short Interest 814 (0%)
Nov 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security